Borderline Personality Disorder (BPD)
Borderline personality disorder (BPD) is fundamentally linked to a dysregulated neural circuitry, primarily characterized by hyperactivity in the amygdala and hypoactivity in the prefrontal cortex. Leveraging our pioneering efforts in BPD research, Protheragen is at the forefront of developing cutting-edge therapies to enhance the effective management of BPD. As your trusted partner in BPD drug development research, we provide unparalleled support to meet your research needs.
Overview of Borderline Personality Disorder (BPD)
Borderline personality disorder (BPD) is a serious psychiatric condition characterized by a pervasive pattern of emotional dysregulation, unstable interpersonal relationships, a distorted sense of self, and marked impulsivity. Key clinical features include intense fears of abandonment, recurrent suicidal behaviors or self-harm, chronic feelings of emptiness, and rapid shifts between idealizing and devaluing others. The disorder has an estimated prevalence of 1-2% in the general population, affecting approximately 75% of diagnosed individuals who are female.
Fig.1 Etiological factors in the development of borderline personality disorder (BPD). (Benzi I M A, et al., 2020)
Pathogenesis of Borderline Personality Disorder (BPD)
Borderline personality disorder (BPD) is a neurobiological abnormality resulting from the interaction of genetic predisposition and environmental factors. Major etiologies include strong heritable factors (estimated at 40-65%) that influence emotion regulation and impulse control, particularly within the serotonin system and other neurotransmitter systems. These genetic predispositions are often activated by environmental adversities, most notably childhood trauma such as abuse or neglect, which can induce epigenetic changes and disrupt neurodevelopment.
Fig.2 Stress response in borderline personality disorder (BPD) subjects according to subjective experience, behavior, neural, neuro-vegetative and neuro-hormonal changes. (Bourvis N, et al., 2017)
Therapeutic Development for Borderline Personality Disorder (BPD)
| Drug Names | Mechanism of Action | Targets | Research Phase |
| Sertraline | Selectively blocks the reuptake of serotonin into the presynaptic neuron, increasing serotonin levels in the synaptic cleft. | Serotonin Transporter (SERT) | Approved |
| Venlafaxine | Blocks the reuptake of both serotonin and norepinephrine, increasing the availability of these neurotransmitters. | Serotonin Transporter (SERT), Norepinephrine Transporter (NET) | Approved |
| Bupropion | Blocks the reuptake of norepinephrine and dopamine, with minimal effect on the serotonin system. | Norepinephrine Transporter (NET), Dopamine Transporter (DAT) | Approved |
| Aripiprazole | Partially activates dopamine D2 receptors to stabilize their activity while modulating serotonin activity (blocking 5-HT2A and partially activating 5-HT1A receptors). | Dopamine D2 and D3 receptors, Serotonin 5-HT1A receptor, Serotonin 5-HT2A receptor | Approved |
Disclaimer: Protheragen focuses on providing preclinical research services. This table is for information exchange purposes only. This table is not a treatment plan recommendation. For guidance on treatment options, please visit a regular hospital.
Our Services
As a leader in rare neuropsychiatric disease research, Protheragen offers comprehensive preclinical services to advance borderline personality disorder (BPD) therapeutics from discovery to validation. Our specialized platforms integrate genetic analysis and disease-specific modeling to replicate disease pathology with high fidelity. Using advanced blood-brain barrier (BBB) models, we optimize central nervous system (CNS) drug delivery while evaluating neuroprotection and off-target effects.
Therapeutic Development Services
By Mechanism of Action
Disease Model Development Services
- Maternal Separation/Deprivation Model: Prolonged daily separation of pups from dam during early postnatal period.
- Social Instability/Defeat Model: Chronic exposure to dominant aggressors or unstable social hierarchies.
Protheragen takes pride in offering comprehensive preclinical research services for borderline personality disorder (BPD) using advanced disease models. These services encompass various aspects of drug research, including pharmacodynamics (PD), pharmacokinetics (PK), and safety evaluations, ensuring a holistic approach towards drug development in this challenging medical area. If you are interested in our services, please feel free to contact us for more details and quotation information of related services.
References
- Benzi I M A, Di Pierro R, De Carli P, et al. All the faces of research on borderline personality pathology: drawing future trajectories through a network and cluster analysis of the literature[J]. Journal of Evidence-Based Psychotherapies, 2020, 20(2): 3-30.
- Bourvis N, Aouidad A, Cabelguen C, et al. How do stress exposure and stress regulation relate to borderline personality disorder?[J]. Frontiers in psychology, 2017, 8: 2054.